ASSAY APPARATUS

Abstract: An assay apparatus (10) including at least one well (13) having an inlet opening (17A), a reaction chamber (16A), a wicking chamber (15A) containing wicking material and filter means (16B) separating the reaction chamber (16A) from the wicking chamber (15A) characterized in that there is provided an upper component (14), including the reaction chamber (16A), and a lower component (15), including the wicking chamber (15A), which upper component (14) and lower component (15) are releasably attachable to each other and are also separated from each other by said filter means (16B) to facilitate reading of analyte bound to the filter means (16B) as well as reading of analyte present in the wicking chamber (15A).

Description: TITLE "ASSAY APPARATUS" FIELD OF THE INVENTION THIS INVENTION relates to assay apparatus for filter-based assays using fluid phase or solid phase incubation for formation of complexes. In particular, the invention relates to assay apparatus for filter based immunoassays, nucleic and cell based receptor binding assay, preferably using fluid phase incubation for formation of immunocomplexes. BACKGROUND OF THE INVENTION Fluid phase immunoassays were first applied by Fazekas de St Groth and Webster, 1961 , Austral. J. Exp. Biol. 39 549-562 and Fazekas de St Groth, 1961 , Austral. J. Exp. Biol. 39 563-582 to separate free antibody from influenza virus-antibody complexes. They used a 50 nm cellulose acetate filter to efficiently separate virus (approximately 80 nm in diameter) from antibody (approximately 24 nm in diameter). Wallis and Melnick, 1965, Virology 26 175-179 showed that echovirus type 4, passed freely through a 220 nm filter without detectable loss of infectivity, as did virus-specific antiserum without loss of titre. However, after mixing virus and specific antibody and allowing immune complexes to form, 85% of infectious virus was retained by the filter and neutralising antibody in filtrates was shown to be reduced by 97-99%. Webster et al., 1968, J. Gen. Virol. 3 315-326 mixed " 125 l- labelled anti-haemagglutinin or 125 l-labelled anti-neuraminidase antiserum with influenza viruses for 30 minutes. The mixtures were passed through 50 nm filters, the filters were washed and their radioactivity counted to estimate the number of neuraminidase antigenic sites on influenza viruses. These authors were the first to describe a membrane filter based radioimmunoassay (RIA) for antigen detection. Brandt et al., 1986, J. Immunol. Methods 95 169-175 developed a competitive enzyme immunoassay for the determination of beta 2-microglobulin in undiluted human serum using a Millititer filter plate and separation by filtration. In Barnett et al., 1987, J. Clin. Microbiol. 25 385-390, Barnett et al., 1988, J. Virol. Meth. 20 323-332, Tannock et al., 1990, Biologicals 19 17-21 as well as in a PhD thesis by G. R. Barnett entitled "The Development and Application of Membrane Filtration Enzyme Immunoassays for the Diagnosis of Viral and Mycoplasmal Infections", there was proposed a filter based enzyme immunoassay (EIA) totally independent of adsorption of antigens or antibodies onto a solid phase. The "membrane filtration enzyme immunoassay" (MFEIA) was applied to a standard 96 well microplate marketed under the MILLITITER trade mark referred to hereinafter wherein the 220 nm pore size of the plates allowed uncomplexed cell-free virus and uncomplexed non-immune immunoglobulin to pass freely through the filters associated with each well whereas virus complexed with antibody was retained on the filter during filtration. Reference may also be made to U.S. Patent 5501949 which also describes a technique similar to the MFEIA technique wherein an immunocomplex comprising a first binding component, second binding component labelled with signal generating material and a sample analyte is trapped on a filter in the presence of insoluble particles allowing for rapid passage of fluid through the filter with subsequent separation of bound and unbound material. The MFEIA technique produced an immune complex in a fluid or liquid phase and separated the complex from the fluid or liquid by filtration so as to isolate the complex on the membrane filter prior to estimation or determination of the amount of complex This technique was intended to replace conventional solid phase immunoassay techniques which relied upon the efficient adsorption of either antigen or antibody onto a solid phase which was usually a solid base surface of a standard 96 well plate formed from plastics material as is known in the art. However, such adsorption was inefficient because many antigens are difficult to adsorb onto plastic surfaces or are easily dislodged by washing steps. In many existing enzyme linked immunosorbent assay (ELISA) kits which were provided commercially, such kits incorporated a solid phase pre-coated with antigen or antibody which was expensive and limited to specific applications or detection or quantitation of specific analytes. The MFEIA technique was also enhanced by the use of microplates which incorporated a plurality of wells, such as a 96 well plate wherein each well was open ended and an open bottom end of each well was in abutment with a filter sheet formed from polymeric membrane which was more specifically low protein binding material identified by the trade mark DURAPORE. Such 96 well plates or "filterplates" were marketed under the trade marks MILLITITER or MULTISCREEN (owned by Millipore Corporation of Bedford, Massachusetts, U.S.A.), and UNIFILTER (owned by Polyfiltronics Inc. of Rockland, Massachusetts, U.S.A.). Such microplates could also be marketed with individual filter discs as is known in the art. Reference may also be made to U.S. Patents which describe the structure of such microplates which include U.S. Patents 4493815, 4704255, 4693834, 4734192, 4797259, 4948442, 5047215, 5205989, 5227290, 5283039, 5409832 and 5679310. Reference also may be made to U.S. Patent 4828386 which refers to a multi-well plate suitable for use in a spectrometer which uses a vertical beam of light comprising a first plate having a plurality of wells for receiving a sample wherein the wells have transparent bottom surfaces to allow for the transmission of a vertical beam of light and a unitary insert comprising a biochemically compatible microporous surface capable of binding biological materials shaped to fit into the wells without interfering with the vertical beam of light. However, disadvantages of the MFEIA technique using conventional microplates as described above are that, in order to draw the fluid through the membrane filter, it is necessary to use vacuum and centrifugal apparatus where the fluid is drawn through by a pressure differential. This also meant that each of the usual components of a microplate assembly, i.e. upper plate having a plurality of wells or apertures, intermediate filter plate and a lower plate component as described in U.S. Patent 4493815 had to be in abutment so that an air tight seal was created. Similar conclusions applied to the microplate assembly referred to in U.S. Patent 4704255. It was also necessary to create specialised abutment structures based on plug socket interconnections between each of the components as described, for example, in U.S. Patents 4948442 or 5047215. Other disadvantages of use of the MFEIA technique using conventional microplates as described above were that incubation volumes and wash volumes are substantial which decreases operational efficiency and increases incubation times of the relevant reagents before the complexes were formed. Another disadvantage of use of the MFEIA technique using conventional microplates as described above was that gravity feed of reagents was normally not possible or appropriate having regard to the fact that it was necessary to draw fluids through the filter using a vacuum. Reference may also be made to U.S. Patent 4632901 which discloses an assay apparatus described in the form of a single well having a porous filter containing a bound receptor for complexing an analyte. In this apparatus, absorbent or wicking material is positioned below the porous filter to assist the fluid sample in flowing through the filter. A labelled antibody is then added to the porous filter to detect the presence or absence of analyte. In this apparatus, however, the entire apparatus was integral in nature which lead to disadvantages of complex construction and an impaired reading efficiency especially if it was desired to read unbound analyte. Reference may also be made to Australian Patent 639703 which related to similar apparatus subject to similar disadvantages. Australian Patent 639703 incorporated an additional modification of a sample well separated from a read well by a transfer passage. There was also an additional requirement for a venting means. Reference may also be made to U.S. Patent 4552839 which refers to analyte detection in a particle containing medium by contacting the medium with bibulous or wicking material wherein particles are concentrated at a position adjacent to the contact site by wicking of particles past the position and a signal associated with these particles can be used to measure the presence of analyte. SUMMARY OF THE INVENTION It therefore is an object of the invention to provide assay apparatus for use in filter based assays which may alleviate one or more of the disadvantages of the prior art. A further object of the invention is to provide an assay method which may also alleviate one or more of the abovementioned disadvantages of the prior art. The assay apparatus of the invention, in a first aspect, includes at least one well having an inlet opening, a reaction chamber, a wicking chamber containing wicking material and filter means separating the reaction chamber from the wicking chamber characterized in that there is provided an upper component, including the reaction chamber, and a lower component, including the wicking chamber, which upper component and lower component are releasably attachable to each other and are also separated from each other by said filter means to facilitate reading of analyte bound to the filter means as well as reading of analyte present in the wicking chamber. It will be appreciated that the terms "upper" and "lower" as used herein have regard to the use of the assay apparatus in practice. Preferably, there is provided a constriction ring in the reaction chamber so as to form a narrow opening or orifice, an incubation chamber and a filtration chamber located below the incubation chamber. Alternatively, there may be provided a peripheral ledge or plurality of projections in the reaction chamber or any other suitable means which may facilitate the formation of a meniscus of assay reagents above the filter means whereby the weight of washing fluid or buffer added to the incubation chamber forces the meniscus of assay reagents into the filtration chamber when desired. The formation of a meniscus above the filter means is especially useful for formation and incubation of complexes involving an analyte and an analyte receptor species in the meniscus prior to trapping of the complex on the filter means by a number of different procedures involving size exclusion where the complex is larger than the pore size of the filter or affinity binding of the complex to a receptor ligand or capture reagent bound to the filter means. The filter means may comprise a polymeric membrane having an average pore size in the region 0.01 to 100 microns, preferably 0.1-5 microns. Viral antigen immune complexes would generally be retained by a pore size of 0.05-0.3 microns whereas a larger pore size may be more appropriate for bacterial antigen immune complexes. Typical membranes are formed of polyvinylidene fluoride and polyamides. The polymer is generally hydrophilic. Alternative materials for the filter means may be cellulose acetate, nylon, nitrocellulose, polyvinyl chloride, teflon and other fluoropolymers, polysulfone, polyester, polycarbonate, paper or glass fibre, quartz, silica or other glass material, ceramic or metallic materials or combinations thereof. The assay apparatus of the invention may include one well or, more preferably, a plurality of wells which may accord with microplates having 8, 12, 24, 48, 96, 384, 864, 1536 or other multiple combinations up to 4356 wells as is known in the art. Generally, the assay apparatus may also include a cover plate if desired although this may not be necessary. In one embodiment, the wicking component may have a light tube preferably having an open end at its base with the wicking chamber preferably of annular cross section surrounding the light tube. The light tube facilitates passage of a light path for reading of a complex deposited on the filter means when required. In this embodiment, the filter means comprises a filter ring which surrounds the light tube as described hereinafter. The assay apparatus of the invention may have wells that are cylindrical, conical, square or other shape dependent upon the requirements of the user. The assay apparatus of the invention is suitably formed from a substantially rigid, water insoluble, fluid- impervious, thermoplastic material chemically unreactive with assay reagents and samples. Suitable materials from which the assay apparatus of the invention is formed include polyvinyl chloride with or without copolymers, polyethylene, teflon and other fluoropolymers, polystyrene and the like. The preferred material is polystyrene. Any convenient bibulous absorbent solid material may be formed as the wicking material which allows for capillary transport of liquids from the filter means. Various materials include cellulose particles, silica gel, cellulosic beads, glass fibres, or filter paper. Preferably the wicking material is porous and can be moulded into complex sizes and shapes from thermoplastic polymers including light density polyethylene, ultra high molecular weight polyethylene, polypropylene, polyvinylidene fluoride, polytetrafluoroethylene, nylon, polyethersulfone and ethyl vinyl acetate. If desired, there also may be employed microparticles which are added with the assay reagents to enhance capture of the complex on the filter means. Such microparticles may be of any convenient size that are suitably small enough that they may form a suspension in aqueous solution to facilitate their coating with an antibody, antigen or oligonucleotide or synthetic compound mimicking the same. The average individual size of the microparticles is about 0.05-100 microns, more preferably 1-10 microns. The microparticles can be selected from any suitable type of particulate material, such as polystyrene, polymethylacrylate, polypropylene, silica, teflon and other fluoropolymers, latex, polytetrafluoroethylene, polyacrylanitrile or polycarbonate. Alternatively, dendrimer or dendrimeric-type molecule reagent preparations can be utilized as described in Australian Patent Applications 22431/95 or 22889/95 in the name of Dade International, Inc. and U.S. Patent No. 5714166. Each of these prior art references are incorporated herein in their entirety. In the assay apparatus of the invention, the use of an incubation chamber component and a wicking chamber component separated by filter means and which also may be releasably attachable to each other is advantageous because after formation of the complex on the filter means, the wicking chamber component may be discarded after reading of any unbound analyte present in the filtrate. It will be appreciated that the assay apparatus of the invention is applicable to the estimation of antigen (inclusive of haptens) or antibody levels and nucleic acid sequence targets. In the estimation of blood antibody levels, the antigen is preferably incubated with blood serum so that any antibodies present form antigen-antibody complexes which may be isolated on the filter means and estimated. Similarly, antigens (such as viral or bacterial antigens) may be estimated by incubation with the respective antibody and isolation on the filter means. Nucleic acid targets (such as viral or bacterial DNA or RNA sequences) may be detected by incubation with an appropriate complementary oligonucleotide probe and isolation of the hybridized product on the filter. Other applications relevant to nucleic acids include isolation of radiolabelled DNA, such as for liquid scintillation counting in tritiated thymidine uptake assays, or for size-based separation of DNA from solution. Detection of nucleic acids could be performed using radioactive fluorescent and colorimetric methods as is well known in the art. The amount of immune complex may be estimated by conventional techniques. For example, the antigen or antibody (as appropriate) may be labelled. The label may be a radioactive label, an enzyme, a fluorescence label or other label known in the art. Alternatively, the antigen-antibody complex might be reacted with a labelled anti-antibody. The amount of labelled complex is then estimated by known methods, i.e. conversion of substrate by an enzyme, radioactive counting of radiolabelled complexes and spectroscopic fluorescence measurements respectively. The use of fluorescence or other visible labels are facilitated by the aforementioned light tube. It may also be possible to produce an antigen-antibody- (anti-antibody) complex by incubation of antigen, antibody and anti- antibody in a single step, thereby saving time. Generally, the immune complex isolated on the filter is washed prior to further treatment, for example, with phosphate buffered saline (PBS). However, this may not be critical in the absence of other interfering species. It is also considered that the invention will also have special relevance to high throughput screening such as combinatorial chemistry libraries. A combinatorial chemistry library of randomly or non-randomly synthesized oligomers may be prepared on solid support materials such as particles, microparticles, resin beads, and the like with many compositions. Libraries prepared on such particles are used in the art by companies searching for new bioactive compounds such as drugs and for compounds useful as diagnostic agents or vaccines (e.g. synthetic amino acid sequences mimicking discontinuous epitopes derived from microorganisms such as bacteria and viruses). The assay apparatus of the invention may be used to incubate such a library of compounds with molecules of interest such as cell surface receptor molecules, enzymes or antibodies. These molecules of interest may be labelled with substances such as enzymes, fluorescent compounds, biotin or other molecules and thus may function as a tracer. Following incubation of the library particles with the labelled tracers, the mixture may be added to reaction chamber 16A. The mixture is allowed to pass through the filter and the filter of the invention may be washed to remove unwanted reagents. The aim is to identify those particles bearing oligomers that have bound to the tracer. This can be done by performing an enzyme assay for the presence of the tracer, which will result in a colour change of the labelled particles. If an encoding system was used during the manufacture of the particle library, it may be possible to decode the oligomer identity directly. Another means of identifying those particles bearing oligomers that have bound to the tracer molecules would be to use tracer molecules conjugated to a specific ligand (e.g. biotin) that will be trapped by a receptor ligand on the filter assembly (e.g. streptavidin). Thus, when the mixtures pass through the filter, particles that have bound the biotinylated tracer molecules will be retained on the filter assembly by biotin-streptavidin binding and all other particles pass through the filter assembly. After washing, the filter assembly will only have on it particles with oligomers that specifically bind to the tracer molecules. Other examples of ligand pairs include oligonucleotide pairs, small peptide binding pairs and metal chelates binding to polyhistidine. BRIEF DESCRIPTION OF THE DRAWINGS Reference may now be made to a preferred embodiment of the invention as shown in the attached drawings, wherein:- FIG. 1 is a top plan view of assay apparatus comprising a 96 well plate constructed in accordance with the invention; FIG. 2 is a perspective view of the well plate shown in FIG. 1 ; FIG. 3 is an exploded perspective view of an individual well of the well plate shown in FIGS. 1-2 or alternatively, an individual well assembly; FIG. 4 is an exploded perspective view of another embodiment of an individual well of the well plate shown in FIGS. 1-2 or alternatively, an individual well assembly; FIG. 5 is a vertical cross section of the well plate or well assembly shown in FIG. 4; FIG. 6 is a horizontal cross section of the well plate or well assembly shown in FIG. 4; FIG. 7 is a view similar to FIG. 5 showing application of a mixture of analyte, capture reagent and detection reagent to the well plate or well assembly; FIG. 8 is a view similar to FIG. 7 showing the application of wash buffer to the well plate or well assembly; FIG. 9 is a view similar to FIG. 7 showing fluids passing into the wicking chamber of the well plate or well assembly; FIG. 10 is a similar view to FIG. 7 showing fluids trapped in the wicking chamber; FIG. 11 is a similar view to FIG. 7 showing more wash buffer being added to the well plate or well assembly; FIG. 12 is a similar view to FIG. 7 showing the wash buffer passing through the filter into the wicking chamber; FIG. 13 is a similar view to FIG. 7 showing additional wash buffer being added to the well plate or well assembly; FIG. 14 is a similar view to FIG. 7 showing the additional wash buffer passing through the filter into the wicking chamber; FIG. 15 is a similar view to FIG. 7 showing chromogen/ substrate being added to the well plate or well assembly; FIG. 16 is a side view of a modified well plate assembly for use in the invention which may be used with samples of larger volumes than the embodiment of FIGS. 3-4; and FIG. 17 is a top plan view of the well plate assembly of FIG. 16. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Reference is made in FIGS. 1-2 to a 96 well plate 10 of the invention labelled on one side 11 with numbers 1-12 and on an adjacent side 12 with letters A-H in conventional manner. The well plate 10 has a plurality of wells 13 which may have a plurality of different cross sections as discussed hereinafter in relation to FIGS. 3-6. It will also be appreciated that individual well plates may comprise 16 wells, as indicated, for example, by line 24-24 in phantom or 32 wells as indicated, for example, by line 48-48 in phantom or 8 wells, as indicated, for example, by the area between lines 120-120 and 132-132 in phantom. In another embodiment, well plates in strip form may be removed from well plate 13 by pulling along line 24-24, 48-48, 120-120 and 132-132 which comprise, for example, a line of perforations or of a cross section which is relatively thin or frangible compared to the remainder of well plate 13. It will also be appreciated that wells 13 may be integral with well plate 10 or be individually mounted on well plate 10 whereby they may be removed from well plate 10 and placed in a separate holder for tests. In FIG. 3, reference is made to well plate assembly 14 including a lower component 15 having a wicking chamber 15A and an upper component 16 having a reaction chamber 16A and filter 16B. There is also provided inlet opening 17A. Well plate assembly 14 is suitable for detection of analyte based on radioactive species or RIA, fluorescence or chemiluminence. Wicking material 17 is fitted into wicking chamber 15A and filter 16B is bonded to upper component 16 at its base 18. There is also provided a continuous constriction 19 which divides upper component 16 or reaction chamber 16A into incubation chamber 16C and filtration chamber 21 with restricted opening 22 located between incubation chamber 16C and filtration chamber 21. The filter 16B may also be retained in wicking chamber 15A if desired. In FIG. 4, reference is made to another well plate assembly 24 which is similar to well plate assembly 14 shown in FIG. 3 with the exception that lower component 15 includes a light path tube 25, wicking chamber 15A, wicking chamber cover 26, filter 16B and cap 24A for light path tube 25. Wicking material 17 is included in wicking chamber 15A. In FIG. 5, reference is made to a vertical cross section of well plate assembly 24 wherein constriction ring 19 prevents fluids flowing directly into filtration chamber 21. Preferably the volume of wicking chamber 15A is approximately 20-200 μL and the volume of the incubation chamber 16C is approximately 20-150 μL and more preferably 60 μl. Fluids of up to 60 μL will not pass through opening 22 but a meniscus 23 will hang below constriction ring 19 as shown in FIG. 7. Flow through opening 22 is initiated when washing fluid is added to incubation chamber 16C, the weight of which forces washing fluid through opening 22 and the meniscus 23 touches filter 16B and wicking material 17, dragging the fluid rapidly into wicking chamber 15A. In FIG. 7, a reaction mixture 27 of analyte 28, capture reagent 29 and detection agent 30 is added to the incubation chamber 16C and incubated. The mixture 27 does not pass through opening 22. In this step of the use of the assay apparatus of the invention, an antibody assay sample containing analyte is added first (i.e. 20 μl) followed by antigen and conjugate (40 μl). This mixture is then incubated. In FIG. 8, wash buffer 31 is added to the reaction mixture 27 and the weight of the wash buffer 31 forces the reaction mixture 27 through opening 22 onto filter 16B and wicking material 17. Subsequently as shown in FIG. 9, fluids rapidly pass through the filter 16B into wicking material 17 as shown by the arrows in full outline. Wicking material 17 absorbs both the reaction mixture 27 and the wash buffer 31 by capillary action. The gap between the meniscus 23 and filter 16B must be adjusted to function as required. If the gap is too great, the capillary action may not occur. Immune complexes 32 have now formed in chamber 16C and filtration chamber 21. Thereafter as shown in FIG. 10, fluids are then trapped in wicking material 17 with the incubation chamber 16C and filtration chamber 21 being empty and immune complexes 32 trapped on filter 16B. Thereafter as shown in FIG. 11 , more wash buffer 31 is added to incubation chamber 16C which, as shown in FIG. 12, passes rapidly through filter 16B into wicking material 17. FIG. 13 shows subsequently the addition of further wash buffer 31 to filtration chamber 21 which, again, as shown in FIG. 14, passes rapidly through filter 16B and into wicking material 17. Finally, as shown in FIG. 15, chromogen/substrate 34 is added to filtration chamber 21 whereby flow through filter 16B is blocked by particles in the diluent of chromogen/substrate 34 rapidly blocking filter 16B. Alternatively, flow through filter 16B may be blocked by silicone addition or filling wicking material 17 with fluid. On contact with the captured immune complexes 32 containing the enzyme conjugated detector reagent, a colour change begins as shown at 35. It will also be appreciated that while FIGS. 7-15 refer to an antigen assay, the assay apparatus of the invention can be used for antibody assays and nucleic acid assays based on a similar procedure. Also, an antibody capture format for the detection of antibody with our without the use of dendrimers or dendrimeric-type molecules or microparticles as carriers may also be utilized. Reference may be made to a further embodiment as shown in FIGS. 16-17 wherein there is provided a well plate assembly 35 having an opening 36 for addition of samples and reagents to reaction chamber 16A. There is also provided filter 16B, light path tube 25 and wicking chamber 15A containing wicking material 17. Well plate 35 as shown is in the form of a strip which corresponds to the length and width of 12 wells normally found on a micro well plate as shown in FIGS. 1-2. The structure of well plate 35 therefore provides for eight strips per 96 well plate wherein each strip tests one sample. All wells will align to column 1 of the plate to facilitate plate reading in the instrument utilized. Variations may include 16, 24 or 48 strips per plate as may be required. The sample is pre-mixed with the test reagents inclusive of capture reagent conjugated to the carrier microparticles, dendrimers or dendrimeric-type molecules by adding to reaction chamber 16A with the left hand side of well plate assembly 35 elevated to prevent fluids touching the filter 16B. Following incubation, the well plate assembly 35 may be oriented to a horizontal orientation allowing the fluids to flow through filter 16B into wicking material 17. The filter 16B may then be washed and chromogen/substrate added followed by stopping solution. It will also be appreciated with 8 strips per well that the reader only needs to read column 1 rows A through H. It will also be appreciated that up to 3 ml or greater volumes may be readily tested with a well plate of the invention incorporating eight strips. In a second aspect of the invention, there is provided an assay apparatus which includes at least one well having an inlet opening, a reaction chamber, a wicking chamber containing wicking material and filter means separating the reaction chamber from the wicking chamber, characterized in that there is provided means to facilitate the formation of a meniscus above the filter means, for example, the aforementioned constriction ring 19. In a third aspect of the invention, there is provided an assay apparatus which includes at least one well having an inlet opening, a reaction chamber, a wicking chamber containing wicking material and filter means separating the reaction chamber from the wicking chamber, characterized in that there is provided a light tube in the wicking chamber, for example, the aforementioned light tube 25. In this aspect, the wicking chamber may be of relatively large volume as shown in FIGS. 16 and 17, which embodiment falls within the scope of the third aspect of the invention. It will also be appreciated in the second and third aspects of the invention that both the reaction chamber and wicking chamber may be integral with each other or bonded to each other by ultrasonics, heat, adhesive, laser or mechanical locking with metallic or non-metallic seals. In a fourth aspect of the invention, there is provided an assay method which includes the following steps:- (1 ) introducing a sample fluid containing at least one analyte together with assay reagents into an incubation zone; (2) forming a meniscus of said sample fluid and assay reagents; (3) introducing washing fluid into the incubation chamber to force said meniscus into a filtration zone located above a filter means; (4) forming a complex of said at least one analyte and said assay reagents on said filter means; (5) drawing fluids containing uncomplexed analyte away from said filter means; and (6) estimating or detecting the presence of analyte in said complex or in a filtrate containing uncomplexed analyte. It will also be appreciated from the foregoing that filter member 16B may have a receptor ligand or capture reagent immobilized thereon for binding to a target ligand-analyte receptor conjugate as described in International Patent Application No. PCT/AU98/.... which is incorporated herein by reference. In this regard, filter member 16B may be removable for analysis when required.

Claims: CLAIMS 1. An assay apparatus including at least one well having an inlet opening, a reaction chamber, a wicking chamber containing wicking material and filter means separating the reaction chamber from the wicking chamber characterized in that there is provided an upper component, including the reaction chamber, and a lower component, including the wicking chamber, which upper component and lower component are releasably attachable to each other and are also separated from each other by said filter means to facilitate reading of analyte bound to the filter means as well as reading of analyte present in the wicking chamber. 2. Assay apparatus as claimed in Claim 1 wherein there is provided means for forming a meniscus in the reaction chamber. 3. Assay apparatus as claimed in Claim 2 wherein said means for forming a meniscus comprises a constriction ring in the reaction chamber having a narrow opening or orifice. 4. Assay apparatus as claimed in Claim 1 or 2 wherein the filter means comprises a polymeric membrane having an average pore size in the region of 0.05-100 microns. 5. Assay apparatus as claimed in Claim 4 wherein the average pore size is within the region 0.1-10 microns. 6. Assay apparatus as claimed in Claim 5 wherein the average pore size is 0.05-0.3 microns. 7. Assay apparatus as claimed in Claim 4 or 5 wherein the membrane is formed from the group consisting of polyvinylidene fluoride, polyamide, cellulose acetate, nitrocellulose, polyvinyl chloride, polysulfone, teflon and other fluoropolymers, polyester, polycarbonate, glass fibre media and surface modified polymeric or ceramic membrane or media. 8. Assay apparatus as claimed in Claim 4 or 5 wherein the membrane is formed from the group consisting of paper, silica, quartz, glass, fibre, ceramic materials and metallic materials. 9. Assay apparatus as claimed in Claim 1 or 2 having a plurality of wells. 10. Assay apparatus as claimed in Claim 9 selected from the group consisting of microplates having 8, 12, 24, 48, 96, 384, 864, 1536 and 3456 wells or any multiple wells. 11. Assay apparatus as claimed in Claim 1 or 2 wherein the wicking component has a light tube to facilitate reading of a complex deposited on the filter means. 12. Assay apparatus as claimed in Claim 11 wherein the light tube has an open end at its base with the wicking chamber surrounding the light tube. 13. Assay apparatus as claimed in Claim 12 wherein the wicking chamber is of annular cross section. 14. Assay apparatus as claimed in Claim 11 or 12 wherein the filter means comprises a filter ring which surrounds the light tube. 15. Assay apparatus as claimed in Claim 1 or 2 wherein the upper component and the lower component are formed from substantially rigid, water insoluble, fluid impervious thermoplastic material chemically unreactive with assay reagents and samples selected from the group consisting of polyvinyl chloride with or without copolymers, polyethylene, teflon and other fluoropolymers, polystyrene and polyvinylidene fluoride. 16. Assay apparatus as claimed in Claim 1 or 2 wherein the wicking chamber is formed from wicking material selected from the group consisting of cellulose particles, silica gel, cellulosic beads, glass fibres and filter paper. 17. Assay apparatus as claimed in Claim 1 or 2 wherein the wicking chamber is formed from wicking material selected from the group consisting of light density polyethylene, ultra-high molecular weight polyethylene, polypropylene, polyvinylidene fluoride, polytetrafluoroethylene, nylon, polyethersulfone and ethyl vinyl acetate. 18. An assay apparatus including at least one well having an inlet opening, a reaction chamber, a wicking chamber containing wicking material and filter means separating the reaction chamber from the wicking chamber, characterized in that there is provided means to facilitate the formation of a meniscus above the filter means. 19. An assay apparatus as claimed in Claim 18 wherein the means for forming a meniscus include a constriction ring in the reaction chamber having a narrow opening or orifice. 20. An assay apparatus including at least one well having an inlet opening, a reaction chamber, a wicking chamber containing wicking material and filter means separating the reaction chamber from the wicking chamber characterized in that there is provided a light tube in the wicking chamber. 21. An assay apparatus as claimed in Claim 20 wherein the light tube has an open end at its base with the wicking chamber surrounding the light tube. 22. An assay apparatus as claimed in Claim 21 wherein the wicking chamber is of annular cross section. 23. An assay method including the following steps:- (1) introducing a sample fluid containing at least one analyte together with assay reagents into an incubation zone whereby a complex is formed between the analyte and the assay reagents; (2) forming a meniscus of said sample fluid; (3) introducing washing fluid into the incubation chamber to force said meniscus into a filtration zone located above a filter means; (4) trapping said complex on said filter means; (5) drawing fluids containing uncomplexed analyte away from said filter means through a wicking zone; and (6) estimating or detecting the presence of analyte in said complex or in a filtrate containing uncomplexed analyte. 24. An assay method including the following steps:- (1) introducing a sample fluid containing at least one analyte together with assay reagents into an incubation zone whereby a complex is formed between the analyte and the assay reagents; (2) trapping said complex on said filter means; (3) drawing fluids containing uncomplexed analyte away from said filter means through a wicking zone; (4) removing said filter means from said incubation zone and/or said wicking zone; and (5) estimating or detecting the presence of analyte in said complex or in a filtrate containing uncomplexed analyte.

Inventors: BARNETT GRAEME ROSS, MANNS ROY L, BARNETT, GRAEME, ROSS, MANNS, ROY, L.
Applicants: BARNETT GRAEME ROSS, MANNS ROY L, PANBIO PTY LTD, BARNETT, GRAEME, ROSS, MANNS, ROY, L., PANBIO PTY. LTD.
Application year: 1998
Main classification: G01N33
IPC codes: C12M1, C12M3, G01N33